News

At ESCRS 2026, Jascha Wendelstein, MD, noted standard ETDRS visual acuity testing misses functional differences between multifocal IOLs that reading-speed testing reveals.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

For decades, topical medications have been the default first-line treatment for glaucoma. However, the well-recognized challenges of daily eye drops, including poor adherence, ocular surface disease, fluctuating intraocular pressure (IOP), and long-term treatment, have fueled a significant transformation in glaucoma therapy. As a result, glaucoma management has undergone a fundamental shift towards laser-based solutions.

Samantha Harding, MD, discusses how ultra-widefield imaging reduces dilation needs and improves diagnosis in paediatric eye care.

At WSPOS Subspecialty Day during the 44th Congress of the ESCRS in London, Mark Bullimore, PhD, MCOptom, shared early trial data suggesting the Stellest 2.0 lens may slow myopic progression twice as fast as the original.

Hove stresses surgeons who prescribe premium lenses or laser surgery to patients should be willing to have those same treatments themselves when needed.

Ana Miguel, MD, PhD, explains how artificial intelligence already outperforms experts in glaucoma screening, expands telemedicine access, and reshapes patient conversations.

Learn who benefits most from Encelto for MacTel type 2, its long-lasting CNTF implant results, and key safety counseling points.

Giuseppe Giannaccare, MD, PhD, FEBOphth, discusses new data on perioperative low-level light therapy for post-cataract dry eye at ESCRS 2026.

NESTS survey reveals patients often normalize dry eye symptoms, delaying care despite major impacts on daily life.

Anat Loewenstein, MD, previews EURETINA 2026 Vienna: the Innovation Spotlight, 17 sessions, symposia, and more.

The 26th EURETINA Congress convenes in Vienna, Austria, from October 1–4, headlined by a new World Retina networking initiative and a revamped Free Paper Forum stage.

At ESCRS 2026, Imane Tarib, MD discusses fostering inclusive ophthalmology workplaces and mentorship for early-career surgeons.

ESCRS 2026 data: patient selection and education may be key to aceclidine (VIZZ; LENZ Therapeutics) persistence.

Alessandro Arrigo, MD, previews an ESCRS 2026 presentation on a patent-pending method that adapts blue light autofluorescence confocal imaging to grade cataracts objectively. The approach yielded reproducible numeric indices that correlated with both expert LOCS III scores and measurable loss of retinal image quality.

Discover how consistent visual outcomes with ZEISS PRESBYOND helped Dr. Gabriel Castro establish a premium refractive surgery practice built on predictability, patient satisfaction, and clinical excellence.

Adam Muzychuk, MD, discusses how AI like the Kane formula is improving outcomes, and why he still urges caution over relying on it for clinical decisions.

Hove explains how his own cataract surgery has changed the way he counsels patients about glare, halos, and near vision.

Jai Parekh, MD, MA, FAAO, says AI is poised to transform eye care—from retinal and glaucoma imaging to cataract surgery—without disrupting it.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.

Radhika Rampat, MBBS, FRCOphth, discusses how AI is already shaping intraocular lens selection and keratoconus screening, and where anterior segment imaging and patient-facing AI tools are headed next.

At the 44th Congress of the ESCRS in London, Mark Bullimore, PhD, MCOptom, said delaying myopia onset is more valuable than slowing its progression, and explained how to identify children most at risk.

Bausch + Lomb's SeeLyra femtosecond laser platform, featuring live OCT imaging, has received CE mark approval for cataract, LASIK, and corneal procedures in Europe.

At ESCRS 2026, Adam Muzychuk, MD, shares real-world data showing the enVista Envy IOL matches clinical trial outcomes, even in eyes with residual refractive error.

Two-year data presented at ESCRS 2026 show the ELIOS excimer laser procedure sustained IOP reduction and kept most glaucoma patients medication-free.

At ESCRS 2026, Zoltan Z. Nagy, MD, reported that femtosecond laser trabeculotomy (FLigHT) cut intraocular pressure by 27% at 48 months in open-angle glaucoma, with a stable, incision-free safety profile.

A prospective French study found intraoperative OCT most valuable for measuring key surgical distances in deep sclerectomy and MIGS procedures, and useful for training residents.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.